Rossari Biotech Reports 38% PAT Growth in Q2 FY24 and Announces ₹178 Cr Capacity Expansion Plans freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
United States Food and Drug Administration completed inspection at Dahej facility and did not issue any Form 483. Last year in September, Ajanta Pharma had received Form 483 for its Dahej facility. Since then the pharma stock was declining.
The company plans to raise up to Rs 300 crore through a fresh issue of shares and offer for sale of up to 8.94 million shares by its current promoter, Snehal Ravjibhai Patel.